Regeneron Pharmaceuticals (NASDAQ:REGN) Given Sector Perform Rating at Royal Bank Of Canada

Key Points

• Royal Bank of Canada reiterated its “sector perform” rating on Regeneron and set a $737 price target, implying about 2% downside from the prior close. The broader analyst consensus remains “Moderate Buy,” with an average target of $802.18.
• Regeneron reported strong quarterly results, posting $14.29 in adjusted EPS versus the $10.16 consensus estimate and $4.29 billion in revenue, up 16.7% year over year.
• Investors are weighing potential pipeline growth from a Libtayo combination trial against competitive pressure to Eylea from Kodiak Sciences’ longer-interval eye treatments; institutional investors own 83.31% of REGN shares.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)'s stock had its "sector perform" rating reiterated by investment analysts at Royal Bank Of Canada in a report released on Tuesday, Benzinga reports. They currently have a $737.00 price objective on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective would indicate a potential downside of 2.03% from the stock's previous close.

A number of other analysts have also weighed in on the company. Truist Financial increased their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research note on Thursday, July 9th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a research note on Wednesday, July 29th. Fourteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $802.18.

Regeneron Pharmaceuticals Stock Down 4.5%

Shares of NASDAQ REGN opened at $752.25 on Tuesday. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm's 50 day simple moving average is $781.41 and its two-hundred day simple moving average is $720.99. The stock has a market capitalization of $77.45 billion, a P/E ratio of 18.59, a PEG ratio of 1.54 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. During the same period last year, the business earned $12.81 earnings per share. The business's quarterly revenue was up 16.7% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares of the company's stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock valued at $3,432,488 over the last ninety days. Insiders own 6.97% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in REGN. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Nuveen LLC lifted its holdings in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $473,872,000. Bank of New York Mellon Corp bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $472,950,000. Finally, Deutsche Bank AG bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $323,249,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Libtayo cancer treatment is being evaluated in combination with Biohaven’s experimental BHV-1530 in patients with solid tumors, with enrollment in the combination cohort already underway. The agreement could support additional clinical applications and potential long-term growth for Libtayo. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results next month, making the upcoming earnings release a potential catalyst. Investors will likely focus on Eylea sales, operating performance and updates on the company’s broader pipeline. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Negative Sentiment: Kodiak Sciences reported Phase 3 data indicating that its investigational eye drugs, Zenkuda and tabirafusp alfa tedromer, matched Eylea on key efficacy endpoints for wet age-related macular degeneration. Their roughly six-month dosing interval, compared with Eylea’s typical eight-week schedule, raises concerns about future competitive pressure and potential pricing or market-share erosion. Kodiak skyrockets on positive study data for two eye drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $737 price target, below the reference price, signaling limited near-term upside in the analyst’s view. Royal Bank of Canada rating update

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.